8 August 2013
Action for M.E. Chief Executive Sonya Chowdhury today called for a collaborative approach to the possible UK-based trial of rituximab, a cancer drug that was shown to help people with M.E. significantly improve in a study published in 2011.
She said, “Action for M.E. has been following the developments in relation to a rituximab trial with great interest. We have been in discussion with a number of other charities, including Invest in M.E., about the trial. Our Board of Trustees will be discussing the trial their next meeting.
“As we have already demonstrated through our funding of the biobank and Disease Register, we are absolutely committed to working collaboratively and this is clearly stated in our research policy.
“Where possible, we will always seek to work collaboratively and would therefore hope to see this level of collaboration going forward with rituximab and other research projects.”
Read our other news stories.